AliveCor, headquartered in United States, remains privately held. Investors last valued the company at $467.2M. No public ticker exists for the company.
One company valuation: $467.2M, dated Aug 2022.
Mayo ClinicLEAD
GE HealthcareLEAD
Khosla VenturesLEADWWP Global PartnersLEADQQualcomm VenturesLEADBBold Capital PartnersLEADBBurrill & CompanyLEADOOMRENGGE HealthCare TechnologiesPPegasus Tech VenturesSSweetwater Private EquityHHuami CorpMayo ClinicGE HealthcareKhosla VenturesAliveCor makes AI-powered ECG devices, including the KardiaMobile line and the KardiaMobile 6L, which delivers a six-lead reading in 30 seconds without wires or patches, plus the Apple Watch-compatible KardiaBand. The company sells to individual patients, biopharma partners tracking drug safety, health systems monitoring patients remotely, and payers and employers managing cardiac health costs.
David Albert, a former chief clinical scientist of cardiology at General Electric, co-founded the company in 2011 in Mountain View, California, with scientists Bruce Satchwell and Kim Barnett, after two decades developing ECG technology for handheld computers. AliveCor partnered with Omron Healthcare to expand access to its heart monitors.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds AliveCor.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. AliveCor availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — AliveCor included.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. AliveCor is a private company; its shares do not trade on a public exchange.
The last valuation is $467.2M.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
